Ex vivo assessment of sulbactam-durlobactam clearance during continuous renal replacement therapy to guide dosing recommendations
Antimicrobial Agents and Chemotherapy · 31.01.2025 · 69 (1)
DOI: 10.1128/aac.01674-23 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 31.01.2025. Verfasst von Yasmeen Abouelhassan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, Connecticut, USA. Hauptthemen laut MEDLINE: Sulbactam, Continuous Renal Replacement Therapy, Anti-Bacterial Agents, Azabicyclo Compounds. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Innoviva Specialty Therapeutics.
Abstract (Originalsprache)
Sulbactam-durlobactam is approved for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex. Patients with serious Acinetobacter infections may require support with continuous renal replacement therapy (CRRT), which presents challenges for optimal dosing of antibiotics. Sulbactam-durlobactam dosing regimens were derived for this population using an ex vivo CRRT model and Monte Carlo simulation (MCS). Transmembrane clearance (CL TM ) was determined in hemofiltration (CVVH) and hemodialysis (CVVHD) modes using the Prismaflex M100 and HF1400 hemofilter sets and with effluent rates of 1, 2, and 3 L/h. Pre-filter, post-filter blood, and effluent samples were collected over 60 min to calculate sieving (SC) and saturation (SA) coefficients for CVVH and CVVHD, respectively. An established population pharmacokinetic model was integrated with the CL TM ; then, a 1,000 patient MCS was conducted to determine exposures of potential dosing regimens. Adsorption and degradation in the ex vivo CRRT model were negligible. The overall mean ± standard deviation SC/SA was 1.14 ± 0.12 and 0.93 ± 0.08 for sulbactam and durlobactam, respectively. In multivariable regression analyses, effluent rate was the primary driver of CL TM for both drugs. For effluent rates
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, Connecticut, USA.
- Innoviva Specialty Therapeutics Inc, Waltham, Massachusetts, USA.
- Division of Nephrology, Hartford Hospital, Hartford, Connecticut, USA.
- Division of Infectious Diseases, Hartford Hospital, Hartford, Connecticut, USA.
ORCID-Profile: David P Nicolau, Joseph L Kuti
Förderung
- Innoviva Specialty Therapeutics
Zitieren
APA
Abouelhassan, Y., Shen, Y., Chen, A., Ye, X., Nicolau, D. P., & Kuti, J. L. (2025). Ex vivo assessment of sulbactam-durlobactam clearance during continuous renal replacement therapy to guide dosing recommendations. Antimicrobial Agents and Chemotherapy, 69(1). https://doi.org/10.1128/aac.01674-23
Vancouver
Abouelhassan Y, Shen Y, Chen A, Ye X, Nicolau DP, Kuti JL. Ex vivo assessment of sulbactam-durlobactam clearance during continuous renal replacement therapy to guide dosing recommendations. Antimicrobial Agents and Chemotherapy. 2025;69(1). doi:10.1128/aac.01674-23
BibTeX
@article{Abouelhassan2025,
author = {Abouelhassan, Yasmeen and Shen, Yuwei and Chen, April and Ye, Xiaoyi and Nicolau, David P and Kuti, Joseph L},
title = {Ex vivo assessment of sulbactam-durlobactam clearance during continuous renal replacement therapy to guide dosing recommendations},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2025},
volume = {69},
number = {1},
doi = {10.1128/aac.01674-23}
}
EUVIMED